• H Sayouri, A Boudier, C Vigneron, P Leroy, and S Le Tacon.
• EA 3452 CITHEFOR, faculté de pharmacie, université de Lorraine, 5, rue A.-Lebrun, BP 80403, 54001 Nancy cedex, France; Service de réanimation pédiatrique, hôpital d'enfants, centre hospitalo-universitaire de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
• Ann Pharm Fr. 2015 Nov 1; 73 (6): 401-10.

AbstractEach year, in France, the number of cardiac arrests is evaluated between 30,000 to 50,000. When a patient survives, he undergoes a post-resuscitation syndrome which can aggravate the injuries and for which nowadays, no medication is available. In some kinds of cardiac arrest, a hypothermia protocol can be applied with a need for monitoring because of the appearance of side effects. In this context, hydrogen sulfide, which is a gasotransmitter with numerous physiological and pharmacological properties, may be interesting. Indeed, its use could protect against oxidative, inflammatory and apoptotic troubles induced by the post-resuscitation syndrome. The implied biochemical mechanisms are adenosine triphosphate potassium channels activation and cytochrome c oxidase inhibition. This molecule can also induce a suspended animation state characterized by a metabolism decrease, which could give a delay for physicians to start a therapeutic monitoring. Thus, in spite of a modest and sometimes contradictory literature, this compound could become the first neuroprotective molecule in cardiac arrest. Copyright © 2015 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.

16 keywords...

hide…